دورية أكاديمية
Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs.
| العنوان: | Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs. |
|---|---|
| المؤلفون: | Barberio J; Department of Epidemiology, Emory University, Atlanta, Georgia, USA.; Center for Observational Research, Amgen Inc., Thousand Oaks, California, USA., Lash TL; Department of Epidemiology, Emory University, Atlanta, Georgia, USA., Nooka AK; Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA., Naimi AI; Department of Epidemiology, Emory University, Atlanta, Georgia, USA., Patzer RE; Department of Epidemiology, Emory University, Atlanta, Georgia, USA.; Regenstrief Institute, Indianapolis, Indiana, USA., Kim C; Center for Observational Research, Amgen Inc., Thousand Oaks, California, USA. |
| المصدر: | Acta haematologica [Acta Haematol] 2024 May 10, pp. 1. Date of Electronic Publication: 2024 May 10. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Karger Country of Publication: Switzerland NLM ID: 0141053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9662 (Electronic) Linking ISSN: 00015792 NLM ISO Abbreviation: Acta Haematol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Karger. |
| مستخلص: | Introduction: Most multiple myeloma (MM) patients experience cytopenias, likely driven by both disease and treatment-related factors. Immunomodulatory agents (IMiDs), which form the backbone of most anti-myeloma regimens, are known to cause higher grade cytopenias. In this context, the impact of sequential IMiD treatments on cytopenia risk is unknown. Methods: We evaluated the cumulative risks of severe cytopenias following second line of therapy (LOT) initiation in 5,573 MM patients in the Flatiron Health database. Patients for whom both LOTs 1 and 2 contained IMiDs were considered "sequentially exposed"; those for whom neither contained IMiDs were "never exposed." Results: For the neutropenia outcome, compared to the never exposed, the sequentially exposed had the highest 1-year risk (risk difference [RD] 12%), followed by those only recently exposed during LOT 2 (RD 8%), then by those with only past exposure during LOT 1 (RD 5%). A similar pattern was observed for leukopenia, but no meaningful differences were observed for anemia or thrombocytopenia. The associations between sequential exposure, versus never, with neutropenia and leukopenia were even stronger among those with a recent cytopenia history. Conclusion: Results suggest that sequential exposure to IMiDs is a risk factor for higher grade cytopenias. These findings have profound clinical implications in choosing newer LOTs with potential risks of cytopenia. (© 2024 S. Karger AG, Basel.) |
| فهرسة مساهمة: | Keywords: Cytopenia; Immunomodulatory drugs; Multiple myeloma; Neutropenia |
| تواريخ الأحداث: | Date Created: 20240512 Latest Revision: 20240715 |
| رمز التحديث: | 20240716 |
| DOI: | 10.1159/000539127 |
| PMID: | 38735288 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1421-9662 |
|---|---|
| DOI: | 10.1159/000539127 |